news
Soft nickases could be the future of safe, effective gene editing
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.
List view / Grid view
Therapeutics
article
Providing new hope for rare disease using non-viral gene therapy
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
article
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
news
EIDD-2801 proven to prevent SARS-CoV-2 infection in vivo
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
news
Thapsigargin could be used as antiviral to treat COVID-19, study shows
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
Novel protein could neutralise SARS-CoV-2 infection in kidneys
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
news
Melatonin could act as barrier against SARS-CoV-2 infection
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
news
Novel nanobody combinations protect cells from SARS-CoV-2 in vitro
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
news
Novel human alveolar tissue model could help COVID-19 drug development
Researchers will use the in vitro model to study how respiratory viruses, like SARS-CoV-2, cause Acute Respiratory Distress Syndrome (ARDS) and develop potential interventions.